Has Mark Sifford, MD received payments from drug or device companies?

Yes. Drug and device makers reported $19,977 in general payments to Mark Sifford, MD across 771 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Sifford, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Sifford, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Sifford, MD

Pulmonary Disease · Jonesboro, ARNPI 1538155791

Payments from drug & device makers

$19,977in general payments, 2019–2025

Across 771 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intuitive Surgical$6K
GSK$3K
AstraZeneca$2K
Boehringer Ingelheim$1K
Jazz Pharmaceuticals Inc.$1K
Pulmonx Corporation$686
plus $6K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intuitive Surgical	18	$5,908
GSK	165	$2,619
AstraZeneca	99	$2,157
Boehringer Ingelheim	77	$1,086
Jazz Pharmaceuticals Inc.	42	$1,039
Pulmonx Corporation	15	$686
Sanofi	29	$665
Regeneron Healthcare Solutions, Inc.	26	$639
Amgen	30	$471
Mylan Specialty L.p.	25	$410
Takeda Pharmaceuticals U.S.A., Inc.	21	$392
Insmed, Inc.	16	$312
Grifols USA, LLC	15	$297
Actelion Pharmaceuticals US, Inc.	17	$269
Genentech USA, Inc.	18	$266
Inspire Medical Systems, Inc.	5	$189
Idorsia Pharmaceuticals US Inc	6	$154
Novartis	9	$146
Johnson & Johnson(2 entities)	12	$145
Daiichi Sankyo Inc.	7	$136
Teva Pharmaceuticals USA, Inc.	7	$109
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$104
Mallinckrodt Hospital Products Inc.	5	$102
Merck	8	$99
Bayer	6	$97
Lilly USA, LLC	6	$94
AbbVie(2 entities)	5	$84
Electromed, Inc.	4	$80
Gilead	6	$79
Verona Pharma, Inc.	4	$75
Novo Nordisk	6	$75
Sumitomo Pharma America, Inc.	5	$72
Medtronic	2	$68
Otsuka America Pharmaceutical, Inc.	2	$54
Aimmune Therapeutics, Inc.	1	$53
Pfizer	3	$48
Harmony Biosciences LLC	1	$45
Philips North America LLC	2	$41
Nestle Healthcare Nutrition Inc.	2	$40
Biohaven Pharmaceuticals, Inc.	2	$37
Advanced Respiratory, Inc	2	$34
United Therapeutics Corporation	2	$33
Baxter Healthcare	2	$33
Abbott	2	$30
Mallinckrodt Enterprises LLC	2	$27
Edwards Lifesciences	1	$25
Sunovion Pharmaceuticals Inc.	2	$24
Circassia Inc.	2	$24
Resmed Corp	1	$22
Vifor Pharma, Inc.	1	$22
Alnylam Pharmaceuticals Inc.	1	$20
Inogen, Inc.	1	$20
Irhythm Technologies, Inc.	1	$19
Corium, LLC	2	$19
Esperion Therapeutics, Inc.	1	$18
Sanofi-aventis U.S. LLC	1	$18
Bristol Myers Squibb	1	$16
Biohaven Pharmaceutical Holding Company Ltd.	1	$16
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$15
Exact Sciences	1	$14

How this compares

$19,977 in reported general payments places this provider in the 90th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas →

Medicare billing

Part B allowed, 2024

$122,338

Medicare patients

896

Services billed

2,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Jonesboro

George Williams IiJonesboro$10K
Jeffrey CohenJonesboro$8K
Grant CagleJonesboro$6K
Mohammad AlnabulsiJonesboro$5K
Larry JohnsonLittle Rock$847K
Timothy CookSherwood$638K
Nikhil MeenaLittle Rock$574K
Raghu ReddyLittle Rock$541K
Ladly AbrahamConway$521K
Daniel PaulRogers$244K

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →